Overview
Permanent congenital hypothyroidism (PCH) is a condition in which the thyroid gland fails to produce adequate amounts of thyroid hormones from birth, and this deficiency persists throughout life, requiring lifelong treatment. Unlike transient forms of congenital hypothyroidism that resolve spontaneously, PCH represents an irreversible defect in thyroid hormone production or action. The condition can result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synthesis), which accounts for most of the remaining cases. Rare forms may also involve defects in thyrotropin (TSH) production or thyroid hormone resistance. Thyroid hormones are critical for normal growth and neurodevelopment, particularly during the first years of life. Without adequate thyroid hormone, affected infants may develop prolonged jaundice, feeding difficulties, constipation, a hoarse cry, hypotonia (decreased muscle tone), a large fontanelle, macroglossia (enlarged tongue), an umbilical hernia, dry skin, and hypothermia. If left untreated, PCH leads to severe and irreversible intellectual disability, growth failure, and delayed skeletal maturation — a condition historically known as cretinism. Newborn screening programs, now implemented in most developed countries, allow early detection of congenital hypothyroidism through measurement of TSH and/or free T4 levels in blood spots collected shortly after birth. Early initiation of levothyroxine (synthetic thyroid hormone) replacement therapy, ideally within the first two weeks of life, is the standard of care and can prevent the neurodevelopmental consequences of the disease. With prompt and adequate treatment, most children with PCH achieve normal cognitive development and growth, though some studies suggest subtle neurocognitive differences may persist. Lifelong monitoring of thyroid function and dose adjustments are essential.
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Permanent congenital hypothyroidism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Permanent congenital hypothyroidism at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Permanent congenital hypothyroidism.
Community
No community posts yet. Be the first to share your experience with Permanent congenital hypothyroidism.
Start the conversation →Latest news about Permanent congenital hypothyroidism
No recent news articles for Permanent congenital hypothyroidism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Permanent congenital hypothyroidism
What is Permanent congenital hypothyroidism?
Permanent congenital hypothyroidism (PCH) is a condition in which the thyroid gland fails to produce adequate amounts of thyroid hormones from birth, and this deficiency persists throughout life, requiring lifelong treatment. Unlike transient forms of congenital hypothyroidism that resolve spontaneously, PCH represents an irreversible defect in thyroid hormone production or action. The condition can result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synth
At what age does Permanent congenital hypothyroidism typically begin?
Typical onset of Permanent congenital hypothyroidism is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Permanent congenital hypothyroidism?
2 specialists and care centers treating Permanent congenital hypothyroidism are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.